With Interchangeability Nod, Viatris' Semglee Loses Its Identity

 
• By Sue Sutter

Now approved as an interchangeable biosimilar, US labeling for Viatris’ insulin aspart mirrors that of Sanofi’s Lantus and has shed data from two studies in type 1 and 2 diabetics that showed noninferiority to Sanofi’s Lantus; Viatris appears in line for one year of exclusivity.

The US FDA's first-ever interchangeable designation opens new roads for biosimilars. • Source: Nielsen Hobbs

More from Biosimilars

More from Biosimilars & Generics